Production (Stage)
Esperion Therapeutics, Inc.
ESPR
$1.17
-$0.03-2.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -5.96% | 33.86% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.96% | 33.86% | |||
| Cost of Revenue | 20.45% | 32.24% | |||
| Gross Profit | -35.70% | 35.73% | |||
| SG&A Expenses | 16.44% | -7.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.44% | 8.68% | |||
| Operating Income | -399.91% | 72.42% | |||
| Income Before Tax | -89.77% | 27.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -89.77% | 27.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -89.77% | 27.79% | |||
| EBIT | -399.91% | 72.42% | |||
| EBITDA | -402.39% | 72.54% | |||
| EPS Basic | -89.27% | 28.05% | |||
| Normalized Basic EPS | -105.25% | 33.69% | |||
| EPS Diluted | -92.66% | 28.05% | |||
| Normalized Diluted EPS | -105.25% | 33.69% | |||
| Average Basic Shares Outstanding | 0.29% | 0.33% | |||
| Average Diluted Shares Outstanding | 0.29% | 0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||